Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine in Pompe Disease
NCT02357225Phase 1Terminated
- Sponsor
- University of Florida
- Start
- Aug 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyridostigmine in Pompe disease, sponsored by University of Florida. Primary endpoints: 6 Minute Walk Test at Day 90, Quantitative Muscle Testing at Day 90 and 5 more. Started Aug 2015; status: terminated.
02
Drugs
pyridostigmine
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT02357225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357225.